Literature DB >> 15862409

Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.

Amir Halkin1, Mandeep Singh, Eugenia Nikolsky, Cindy L Grines, James E Tcheng, Eulogio Garcia, David A Cox, Mark Turco, Thomas D Stuckey, Yingo Na, Alexandra J Lansky, Bernard J Gersh, William W O'Neill, Roxana Mehran, Gregg W Stone.   

Abstract

OBJECTIVES: We sought to develop a simple risk score for predicting mortality after primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI).
BACKGROUND: Accurate risk stratification after primary PCI is important. Previous risk scores after reperfusion therapy have incorporated clinical +/- angiographic variables but have not considered baseline left ventricular function. Moreover, prior studies have not been validated against independent databases or studies.
METHODS: The databases from the two largest multicenter, randomized AMI trials of primary PCI were utilized for score derivation (the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications [CADILLAC] trial, n = 2,082) and subsequent validation (the Stent-Primary Angioplasty in Myocardial Infarction [Stent-PAMI] trial, n = 900). Logistic regression and the jackknife procedure were used to select correlates of one-year mortality that were subsequently weighted and integrated into an integer scoring system.
RESULTS: Seven variables selected from the initial multivariate model were weighted proportionally to their respective odds ratio for one-year mortality (age >65 years [2 points], Killip class 2/3 [3 points], baseline left ventricular ejection fraction <40% [4 points], anemia [2 points], renal insufficiency [3 points], triple-vessel disease [2 points], and post-procedural Thrombolysis In Myocardial Infarction flow grade [2 points]). Three strata of risk were defined (low risk, score 0 to 2; intermediate risk, score 3 to 5; and high risk, score >/=6) with excellent prognostic accuracy for survival in the derivation and validation sets (c statistics = 0.83 and 0.81 for 30-day mortality and 0.79 and 0.78 for 1-year mortality, respectively).
CONCLUSIONS: In AMI patients treated with primary PCI, seven risk factors readily available at the time of intervention accurately predict short- and long-term mortality. Of note, measurement of baseline left ventricular function is the single most powerful predictor of survival and should be incorporated into risk score models.

Entities:  

Mesh:

Year:  2005        PMID: 15862409     DOI: 10.1016/j.jacc.2005.01.041

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  111 in total

Review 1.  The Role of Fractional Flow Reserve and Instantaneous Wave-Free Ratio Measurements in Patients with Acute Coronary Syndrome.

Authors:  Abdul Rahman Ihdayhid; Jin-Sin Koh; John Ramzy; Arnav Kumar; Michael Michail; Adam Brown; Habib Samady
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

Review 2.  Role of Sam68 as an adaptor protein in signal transduction.

Authors:  S Najib; C Martín-Romero; C González-Yanes; V Sánchez-Margalet
Journal:  Cell Mol Life Sci       Date:  2005-01       Impact factor: 9.261

3.  Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study.

Authors:  Spyridon Liosis; Timm Bauer; Rudolf Schiele; Helmut Gohlke; Martin Gottwik; Hugo Katus; Georg Sabin; Ralf Zahn; Steffen Schneider; Bernhard Rauch; Jochen Senges; Uwe Zeymer
Journal:  Clin Res Cardiol       Date:  2013-06-06       Impact factor: 5.460

4.  Early discharge after primary percutaneous coronary intervention for ST-elevation myocardial infarction.

Authors:  Awsan Noman; Azfar G Zaman; Clyde Schechter; Karthik Balasubramaniam; Rajiv Das
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-09

5.  [The Wearable Cardioverter-Defibrillator (WCD)].

Authors:  Thomas M Helms; A Müller; J O Schwab; D Bänsch; C Karle; T Klingenheben; C Zugck; C Perings
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-05-05

Review 6.  Explicit risk in acute coronary syndrome management.

Authors:  Merril L Knudtson; Colleen M Norris; P Diane Galbraith; Jaro Hubacek; William A Ghali
Journal:  Can J Cardiol       Date:  2009-06       Impact factor: 5.223

Review 7.  [Ventricular tachycardia in postinfarction patients and coronary heart disease. Treatment and prognostic significance].

Authors:  Ingo Wickenbrock; Christian Perings
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2014-01-24

8.  Combined impact of chronic kidney disease and contrast-induced nephropathy on long-term outcomes in patients with ST-segment elevation acute myocardial infarction who undergo primary percutaneous coronary intervention.

Authors:  Hidefumi Nakahashi; Masami Kosuge; Kentaro Sakamaki; Masayoshi Kiyokuni; Toshiaki Ebina; Kiyoshi Hibi; Kengo Tsukahara; Noriaki Iwahashi; Shotaro Kuji; Mari S Oba; Satoshi Umemura; Kazuo Kimura
Journal:  Heart Vessels       Date:  2016-04-22       Impact factor: 2.037

9.  The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.

Authors:  Vivian G Ng; Alexandra J Lansky; Stephanie Meller; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce Brodie; Ruchit Shah; Roxana Mehran; Gregg W Stone
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-10-03

10.  A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score.

Authors:  Davide Capodanno; Piera Capranzano; Rita Bucalo; Alessandra Sanfilippo; Cettina Ruperto; Anna Caggegi; Gianpaolo Ussia; Alfredo Ruggero Galassi; Corrado Tamburino
Journal:  Clin Res Cardiol       Date:  2009-02-13       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.